Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Current Deferred Revenue (2020 - 2022)

Historic Current Deferred Revenue for Therapeutics (RAPT) over the last 3 years, with Q1 2022 value amounting to $645000.0.

  • Therapeutics' Current Deferred Revenue fell 7942.58% to $645000.0 in Q1 2022 from the same period last year, while for Mar 2022 it was $645000.0, marking a year-over-year decrease of 7942.58%. This contributed to the annual value of $1.0 million for FY2021, which is 7519.53% down from last year.
  • According to the latest figures from Q1 2022, Therapeutics' Current Deferred Revenue is $645000.0, which was down 7942.58% from $1.0 million recorded in Q4 2021.
  • Over the past 5 years, Therapeutics' Current Deferred Revenue peaked at $6.0 million during Q2 2020, and registered a low of $645000.0 during Q1 2022.
  • Over the past 3 years, Therapeutics' median Current Deferred Revenue value was $3.1 million (recorded in 2021), while the average stood at $3.3 million.
  • In the last 5 years, Therapeutics' Current Deferred Revenue plummeted by 4562.01% in 2021 and then tumbled by 7942.58% in 2022.
  • Therapeutics' Current Deferred Revenue (Quarter) stood at $4.1 million in 2020, then crashed by 75.2% to $1.0 million in 2021, then plummeted by 36.52% to $645000.0 in 2022.
  • Its Current Deferred Revenue was $645000.0 in Q1 2022, compared to $1.0 million in Q4 2021 and $1.5 million in Q3 2021.